What is the best way to radiate the prostate in 2016?

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 2, 2017, Pages 59-68

  Moon, Dominic H ^a   Efstathiou, Jason A ^b   Chen, Ronald C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Brachytherapy; Hypofractionation; Image guided radiation therapy (IGRT); Intensity modulated radiation therapy (IMRT); Prostate cancer; Proton therapy; Radiation therapy; Stereotactic body radiation therapy (SBRT)

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; QUALITY OF LIFE; RADIATION RESPONSE; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84979669592     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.06.002     Document Type: Review

References (84)

1. [1] Warde, P., Mason, M., Ding, K., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378 (2011), 2104–2111.
2. [2] Widmark, A., Klepp, O., Solberg, A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373 (2009), 301–308.
3. [3] Thoms, J., Bristow, R.G., DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20 (2010), 217–222.
4. [4] Dearnaley, D.P., Khoo, V.S., Norman, A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999), 267–272.
5. [5] Storey, M.R., Pollack, A., Zagars, G., Smith, L., Antolak, J., Rosen, I., Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000), 635–642.
6. [6] Pilepich, M.V., Krall, J.M., Sause, W.T., et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate—analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13 (1987), 351–357.
7. [7] Pilepich, M.V., Asbell, S.O., Krall, J.M., et al. Correlation of radiotherapeutic parameters and treatment related morbidity—analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 13 (1987), 1007–1012.
8. [8] Morris, D.E., Emami, B., Mauch, P.M., et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62 (2005), 3–19.
9. [9] Koper, P.C., Stroom, J.C., van Putten, W.L., et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 43 (1999), 727–734.
10. [10] Marks, L.B., Yorke, E.D., Jackson, A., et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76:Suppl. 3 (2010), S10–19.
11. [11] Kuban, D.A., Tucker, S.L., Dong, L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 67–74.
12. [12] Zietman, A.L., Bae, K., Slater, J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28 (2010), 1106–1111.
13. [13] Dearnaley, D.P., Jovic, G., Syndikus, I., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15 (2014), 464–473.
14. [14] Beckendorf, V., Guerif, S., Le Prisé, E., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80 (2011), 1056–1063.
15. [15] Al-Mamgani, A., van Putten, W.L., Heemsbergen, W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008), 980–988.
16. [16] Swisher-McClure, S., Mitra, N., Woo, K., Smaldone, M., Uzzo, R., Bekelman, J.E., Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 89 (2014), 103–112.
17. [17] Dearnaley, D.P., Sydes, M.R., Graham, J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
18. [18] Yu, C.X., Amies, C.J., Svatos, M., Planning and delivery of intensity-modulated radiation therapy. Med Phys 35 (2008), 5233–5241.
19. [19] Ling, C.C., Burman, C., Chui, C.S., et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35 (1996), 721–730.
20. [20] Bauman, G., Rumble, R.B., Chen, J., Loblaw, A., Warde, P., Expert Panel MotII. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol) 24 (2012), 461–473.
21. [21] Cahlon, O., Zelefsky, M.J., Shippy, A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71 (2008), 330–337.
22. [22] Al-Mamgani, A., Heemsbergen, W.D., Peeters, S.T., Lebesque, J.V., Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009), 685–691.
23. [23] Zelefsky, M.J., Fuks, Z., Happersett, L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000), 241–249.
24. [24] Zelefsky, M.J., Levin, E.J., Hunt, M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 1124–1129.
25. [25] Bekelman, J.E., Mitra, N., Efstathiou, J., et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81 (2011), e325–334.
26. [26] Sheets, N.C., Goldin, G.H., Meyer, A.M., et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. J Am Med Assoc 307 (2012), 1611–1620.
27. [27] van der Heide, U.A., Kotte, A.N., Dehnad, H., Hofman, P., Lagenijk, J.J., van Vulpen, M., Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 82 (2007), 38–45.
28. [28] Langen, K.M., Zhang, Y., Andrews, R.D., et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 62 (2005), 1517–1524.
29. [29] Willoughby, T.R., Kupelian, P.A., Pouliot, J., et al. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 65 (2006), 528–534.
30. [30] Wortel, R.C., Incrocci, L., Pos, F.J., et al. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 91 (2015), 737–744.
31. [31] Sandhu, A., Sethi, R., Rice, R., et al. Prostate bed localization with image-guided approach using on-board imaging: reporting acute toxicity and implications for radiation therapy planning following prostatectomy. Radiother Oncol 88 (2008), 20–25.
32. [32] Chung, H.T., Xia, P., Chan, L.W., Park-Somers, E., Roach, M., Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys 73 (2009), 53–60.
33. [33] Sveistrup, J., af Rosenschöld, P.M., Deasy, J.O., et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol, 9, 2014, 44.
34. [34] Zelefsky, M.J., Kollmeier, M., Cox, B., et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 125–129.
35. [35] Mohler, J.L., Armstrong, A.J., Bahnson, R.R., et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw 14 (2016), 19–30.
36. [36] Grimm, P., Billiet, I., Bostwick, D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:Suppl. 1 (2012), 22–29.
37. [37] Sanda, M.G., Dunn, R.L., Michalski, J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008), 1250–1261.
38. [38] Chen, R.C., Clark, J.A., Talcott, J.A., Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 27 (2009), 3916–3922.
39. [39] Sathya, J.R., Davis, I.R., Julian, J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005), 1192–1199.
40. [40] Hoskin, P.J., Rojas, A.M., Bownes, P.J., Lowe, G.J., Ostler, P.J., Bryant, L., Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103 (2012), 217–222.
41. [41] Morris, W.J., Tyldesley, S., Pai, H.H., et al. ASCENDE-RT⁎: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol, 33(suppl 7), 2015 [Abstr 3].
42. [42] Particle Therapy Co-Operative Group. http://www.ptcog.ch/ [accessed 24.02.16].
43. [43] Trofimov, A., Nguyen, P.L., Coen, J.J., et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 69 (2007), 444–453.
44. [44] Vargas, C., Fryer, A., Mahajan, C., et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 744–751.
45. [45] Coen, J.J., Bae, K., Zietman, A.L., et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys 81 (2011), 1005–1009.
46. [46] Nihei, K., Ogino, T., Onozawa, M., et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys 81 (2011), 390–396.
47. [47] Mendenhall, N.P., Hoppe, B.S., Nichols, R.C., et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 88 (2014), 596–602.
48. [48] Slater, J.D., Rossi, C.J., Yonemoto, L.T., et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 (2004), 348–352.
49. [49] Fang, P., Mick, R., Deville, C., et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 121 (2015), 1118–1127.
50. [50] Gray, P.J., Paly, J.J., Yeap, B.Y., et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119 (2013), 1729–1735.
51. [51] Hoppe, B.S., Michalski, J.M., Mendenhall, N.P., et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120 (2014), 1076–1082.
52. [52] Kim, S., Shen, S., Moore, D.F., et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 60 (2011), 908–916.
53. [53] Yu, J.B., Soulos, P.R., Herrin, J., et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 105 (2013), 25–32.
54. [54] Brenner, D.J., Martinez, A.A., Edmundson, G.K., Mitchell, C., Thames, H.D., Armour, E.P., Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002), 6–13.
55. [55] Fowler, J., Chappell, R., Ritter, M., Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001), 1021–1031.
56. [56] Lee, W.R., Prostate cancer and the hypofractionation hypothesis. J Clin Oncol 31 (2013), 3849–3851.
57. [57] Pollack, A., Walker, G., Horwitz, E.M., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
58. [58] Arcangeli, G., Saracino, B., Gomellini, S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (2010), 11–18.
59. [59] Arcangeli, S., Strigari, L., Gomellini, S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1172–1178.
60. [60] Lee WR, Digman JJ, Amin M, et al. NRG Oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. Abstract LBA6; 2015 ASTRO meeting.
61. [61] Incrocci L, Wortel RC, Aluwini S, et al. Hypofractionated vs conventionally fractionated radiotherapy for prostate cancer: 5-year oncologic outcomes of the Dutch Randomized Phase 3 HYPRO Trial. Abstract LBA2; ASTRO 2015 meeting.
62. [62] Dearnaley D. Five year outcomes of a phase 3 randomized trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): CHHiP investigators group. Abstract 8LBA. European Cancer Congress 2015.
63. [63] Kim, D.W., Cho, L.C., Straka, C., et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89 (2014), 509–517.
64. [64] Kim, D.W., Straka, C., Cho, L.C., Timmerman, R.D., Stereotactic body radiation therapy for prostate cancer: review of experience of a multicenter phase I/II dose-escalation study. Front Oncol, 4, 2014, 319.
65. [65] Madsen, B.L., Hsi, R.A., Pham, H.T., Fowler, J.F., Esagui, L., Corman, J., Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007), 1099–1105.
66. [66] Loblaw, A., Cheung, P., D׳Alimonte, L., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 107 (2013), 153–158.
67. [67] King, C.R., Brooks, J.D., Gill, H., Presti, J.C., Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), 877–882.
68. [68] McBride, S.M., Wong, D.S., Dombrowski, J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118 (2012), 3681–3690.
69. [69] Bolzicco, G., Favretto, M.S., Satariano, N., Scremin, E., Tambone, C., Tasca, A., A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol, 13, 2013, 49.
70. [70] Katz, A.J., Kang, J., Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol, 4, 2014, 240.
71. [71] Katz, A.J., Kang, J., Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol, 4, 2014, 301.
72. [72] Chen, L.N., Suy, S., Uhm, S., et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol, 8, 2013, 58.
73. [73] Oliai, C., Lanciano, R., Sprandio, B., et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2 (2013), 63–70.
74. [74] King, C.R., Freeman, D., Kaplan, I., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109 (2013), 217–221.
75. [75] King, C.R., Collins, S., Fuller, D., et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 87 (2013), 939–945.
76. [76] Lukka H, Pugh S, Bruner D, et al. Patient reported outcomes in NRG Oncology/RTOG 0938, a randomized phase II study evaluating two ultra-hypofractionated regimens (UHR) for prostate cancer. Abstract LBA3. 2015 ASTRO meeting.
77. [77] ASTRO model policies: stereotactic body radiation therapy (SBRT); 2014. https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROSBRTModelPolicy.pdf [accessed Feb 24, 2016].
78. [78] Palma, D., Vollans, E., James, K., et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 72 (2008), 996–1001.
79. [79] Zhang, P., Happersett, L., Hunt, M., Jackson, A., Zelefsky, M., Mageras, G., Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys 76 (2010), 1456–1462.
80. [80] Bastasch, M.D., Teh, B.S., Mai, W.Y., McGary, J.E., Grant, W.H., Butler, E.B., Tolerance of endorectal balloon in 396 patients treated with intensity-modulated radiation therapy (IMRT) for prostate cancer. Am J Clin Oncol 29 (2006), 8–11.
81. [81] Cho, J.H., Lee, C.G., Kang, D.R., et al. Positional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy. J Korean Med Sci 24 (2009), 894–903.
82. [82] Kim, H., Kim, J.W., Hong, S.J., et al. Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon. Radiat Oncol J 32 (2014), 187–197.
83. [83] Mariados, N., Sylvester, J., Shah, D., et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92 (2015), 971–977.
84. [84] Chen, R.C., Rumble, R.B., Loblaw, D.A., et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 34 (2016), 2182–2190.